Clinical Trial Update: A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

A Phase 2a trial evaluating SYT-510 in Generalized Anxiety Disorder is underway, assessing efficacy, safety, tolerability, and pharmacokinetics; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• SYT-510

Snippet

Sponsor: Synendos Therapeutics AG | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: NOT_YET_RECRUITING